A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
NCT ID: NCT02132312
Last Updated: 2021-07-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
78 participants
INTERVENTIONAL
2014-07-31
2016-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
No Drop Post-Op Cataract Surgery
NCT03864133
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
NCT01193127
Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.
NCT00721695
Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
NCT01454063
Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
NCT01579565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intraoperative pupil size will be determined by measurement of pupil diameter from still photos captured from video recordings of the procedure. Pupil diameter measurements will be performed immediately prior to the initial incision and at one-minute intervals until the end of the procedure (wound closure). Pain will be assessed by the Alder Hey Triage Pain Score.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OMS302
OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
OMS302
Phenylephrine HCl
Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
Phenylephrine HCl
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OMS302
Phenylephrine HCl
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Are to undergo unilateral primary cataract extraction with or without lens replacement.
3. Have informed consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization provided by a parent or legal guardian in accordance with local regulations and governing IRB/IEC requirements prior to any procedures or evaluations performed specifically for the sole purpose of this study.
4. A parent or legal guardian has indicated that they understand and are able, willing, and likely to fully comply with study procedures and restrictions.
Exclusion Criteria
2. Hypersensitivity to phenylephrine, ketorolac, or other NSAIDs, including aspirin, or latex.
3. Surgeon's expectation that the protocol-specified mydriatic regimen will not be adequate to perform the procedure and that additional mydriatic treatment (pharmacological or mechanical) will be required.
4. Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the Investigator.
5. Presence of active or suspected viral, bacterial, or fungal disease in the study eye.
6. Use of any topical medication in the study eye within seven days prior to surgery, except for medications needed to examine the eye or prepare for surgery.
7. Have a post-traumatic cataract.
8. History of uveitis or evidence of past uveitis such as synechiae or keratic precipitates in the study eye.
9. Have an ocular neoplasm in the study eye.
10. Have a clinically significant infection.
11. Have suspected permanent or low vision in the fellow non-study eye, unless caused by a cataract. The study eye must not be the subject's only good eye.
12. Use of systemic corticosteroids or NSAIDs in the seven days prior to surgery.
13. Have a history of clinically significant corticosteroid-induced intraocular pressure increase.
14. Use of any medication for ocular hypertension or glaucoma in the study eye.
15. Use of monoamine oxidase inhibitors for 21 days preoperatively.
16. Prior participation in a clinical study of OMS302.
17. Participating in any investigational drug or device trial within the 30 days prior to the day of surgery.
18. History of intraocular non-laser surgery in the study eye within the three months prior to the day of surgery, or intraocular laser surgery in the study eye within 30 days prior to the day of surgery.
19. Presence of any condition that the Investigator believes would put the subject at risk or confound the interpretation of the study data.
20. Be a member of the immediate family of the Investigator or employees of the investigative site. Immediate family is defined as the Investigator's or employees' natural or legally adopted child (including a stepchild living in the Investigator's household), or grandchild.
1 Day
47 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Omeros Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steve Whitaker, MD
Role: STUDY_DIRECTOR
Omeros Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles, California, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Kansas City, Kansas, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Charleston, North Carolina, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wilson ME, Trivedi RH, Plager DA. Safety and efficacy data supporting U.S. FDA approval of intracameral phenylephrine and ketorolac 1.0%/0.3% for pediatric cataract surgery: clinical safety and pupil and pain management. J Cataract Refract Surg. 2020 Jun;46(6):873-878. doi: 10.1097/j.jcrs.0000000000000194.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OMS302-ILR-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.